Prof. Dr. André Rosenthal is the director ad interim of the Laboratoire national de santé (LNS) until a new director is appointed.

With a scientific background in molecular biology, human and molecular genetics and translational oncology, André Rosenthal was a key member of the International Human Genome Project. He headed the German human genome sequencing program. His team at the Institute of Molecular Biotechnology (IMB) at Friedrich Schiller University in Jena, Germany, was responsible for the sequencing of chromosome 21 and significant parts of the human X chromosome.

As an entrepreneur, André Rosenthal founded Signature Diagnostics, a cancer diagnostic company in Germany today owned by Roche. Within Signature and Roche Diagnostics he worked on next generation sequencing (NGS) assays for circulating tumor DNA and its use for minimal residual disease detection in early stage colorectal cancer and monitoring patients with advanced NSCLC (Non-Small Cell Lung Cancer) and SCLC (Small Cell Lung Cancer). His work supported the development of the AVENIO ctDNA kit. André Rosenthal is also the CEO and co-founder of Fertiga, a Belgian company in the field of female fertility that developed a gene test for oocyte quality, and the President and co-founder of Lavima Fertility, an American company active in the development of new technologies for the in vitro maturation of oocytes.

André Rosenthal is the author and co-author of over 140 articles and the inventor of over 30 patents.